MorphoSys AG: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting Its Potential Application in a Broad Array of Advanced Tumors

The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys

Related Keywords

Germany ,United States ,Planegg ,Bayern ,Massachusetts ,Washington ,Boston ,Sweden ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Swedish ,American ,Thomas Biegi ,Tim Demuth ,Julia Neugebauer ,Eamonn Nolan ,Charles Drescher ,Morphosys Agview ,Gynecologic Cancer Research ,Swedish Cancer Institute In Seattle ,Development Officer ,Linkedin ,National Cancer Institute ,Twitter ,European Organisation For Research ,Exchange Commission ,American Association For Cancer Research ,Molecular Targets ,Cancer Therapeutics ,European Organisation ,American Association ,Cancer Research ,Gynecologic Oncologist ,Medical Director ,Swedish Cancer Institute ,Morphosys Chief Research ,Morphosy Annual Report ,Morphosys ,Presents ,Reliminary ,Results ,Rom ,Hase ,Study ,Tulmimetostat ,Supporting ,Potential ,Application ,Road ,Array ,Dvanced ,Rumors ,